To see the other types of publications on this topic, follow the link: OMA-1.
Journal articles on the topic 'OMA-1'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'OMA-1.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Kahraman, Gülten, Mustafa Türk, Zakir M. O. Rzayev, M. Elif Unsal, and Ernur Söylemez. "Bioengineering functional copolymers. XV. Synthesis of organoboron amide-ester branched derivatives of oligo(maleic anhydride) and their interaction with HeLa and L929 fibroblast cells." Collection of Czechoslovak Chemical Communications 76, no. 8 (2011): 1013–31. http://dx.doi.org/10.1135/cccc2010080.
Full textAbstract:
Novel bioengineering functional organoboron oligomers were synthesized by (i) amidolysis of oligo(maleic anhydride) (OMA) with 2-aminoethyldiphenylborinate (2-AEPB), (ii) esterification of organoboron oligomer (OMA-B) with α-hydroxy-ω-methoxypoly(ethylene oxide) (PEO) as a compatibilizer and (iii) conjugation of organoboron PEO branches (OMA-B-PEO) with folic acid as a taggering agent. Structure and composition of the synthesized oligomers were characterized by FTIR-ART and 1H (13C) NMR spectroscopy, chemical and physical analysis methods. Interaction of functional oligomers and oligomer···FA complex (OMA-B-PEO-F) with HeLa and L929 fibroblast cells were investigated by using different biochemical methods such as cytotoxicity, statistical, apoptotic and necrotic cell indexes, double staining and caspase-3 immunostaining, light and fluorescence inverted microscope analyses. It was found that citotoxisity and apoptotic/necrotic effects of oligomers significantly depend on the structure and composition of studied oligomers, and increase the following raw: OMA << OMA-B < OMA-B-PEO < OMA-B-PEO-F. A folic acid complex (MA-PEG-B-F) at 400 μg ml–1 (2.36 μmol ml–1) concentration as a therapeutic drug exhibits minimal toxcisity toward the fibroblast cells, but influential for HeLa cells.
2
Wong, Victor, Linda Szeto, Kristine Uffelman, I. George Fantus, and Gary F. Lewis. "Enhancement of muscle glucose uptake by the vasopeptidase inhibitor, omapatrilat, is independent of insulin signaling and the AMP kinase pathway." Journal of Endocrinology 190, no. 2 (August 2006): 441–50. http://dx.doi.org/10.1677/joe.1.06396.
Full textAbstract:
Omapatrilat (OMA), a vasopeptidase inhibitor (VPI), presently being tested in clinical trials for its antihypertensive properties, inhibits both angiotensin-converting enzyme and neutral endopeptidase, and raises tissue bradykinin levels. Recent studies from our laboratory and those of others have demonstrated that VPIs enhance muscle glucose uptake in animal models, and this effect is mediated by the bradykinin–nitric oxide pathway. The mechanism of the effect of OMA on muscle glucose uptake, however, is presently unknown. To investigate the effect of OMA on insulin signaling, soleus muscle was isolated 2 or 5 min after an i.v. bolus of insulin or saline from male Zucker fatty rats (8–10 weeks of age), following a 5-day treatment period of oral OMA (15 mg/kg per day) or drug vehicle (placebo). OMA resulted in significantly lower systolic blood pressure compared with the placebo-treated group (84.4± 7.52 mmHg in OMA vs 112±2.18 mmHg in controls, P<0.01). Immunoprecipitation and Western blot analysis of insulin receptor substrate 1 (IRS-1) revealed no changes in protein mass with OMA treatment. OMA did not enhance basal or insulin-stimulated IRS-1 tyrosine phosphorylation or its subsequent association with the p85 regulatory subunit of phosphatidylinositol 3-kinase. Under basal and insulin-stimulated conditions, OMA treatment did not alter the protein mass or the phosphorylation of Akt/protein kinase B, p42/44 extracellular signal-regulated kinase or adenosine monophosphate-activated protein kinase, or GLUT4 protein expression. We conclude that the ability of OMA to enhance whole body and specifically muscle glucose uptake in Zucker fatty rats is not mediated by enhancing insulin or AMPK signaling. Future studies should examine whether hemodynamic effects of the drug, independent of insulin signaling, enhance glucose uptake in insulin-resistant skeletal muscle.
3
Rahman, Haizuan Abd, and Ahmad Azlan Mat Isa. "The Effectiveness of Operational Modal Analysis (OMA) for Detecting Saw Cut Damage in Fiberglass Reinforced Epoxy." Applied Mechanics and Materials 393 (September 2013): 649–54. http://dx.doi.org/10.4028/www.scientific.net/amm.393.649.
Full textAbstract:
This study attempts to apply vibration based damage detection method specifically operational modal analysis (OMA) on fiberglass reinforced epoxy plate. OMA is used on undamaged fiber glass reinforced epoxy plate to extract the modal parameters and after which the procedure is extended to saw cut damage fiberglass reinforced epoxy plate. Both healthy and damaged composite material are tested for different boundary conditions i.e. free-free on 4 edges, 1 edge clamped, 2 edges clamped, 3 edges clamped and 4 edges clamped condition. Then result of frequency from OMA was compared analytically with finite element method. Based on the results, it shows that a high deviation between OMA and finite element method can be observed. Result of frequency from OMA was then compared with Experimental Modal Analysis (EMA) to validate the effectiveness of OMA method. It is shown that results obtained from OMA are in good correlation with results obtained from EMA.
4
Nazarudin, Nurbaiti. "OTITIS MEDIA AKUT DENGAN KOMPLIKASI MASTOIDITIS AKUT DAN LABIRINTITIS AKUT PADA DEWASA." Medika Kartika Jurnal Kedokteran dan Kesehatan, Volume 4 No 1 (October 31, 2020): 23–34. http://dx.doi.org/10.35990/mk.v4n1.p23-34.
Full textAbstract:
Otitis media akut (OMA) merupakan penyakit infeksi pada telinga tengah yang disebabkan oleh bakteri. Walaupun OMA paling sering terjadi pada usia 6 bulan sampai 3 tahun, tetapi dapat juga terjadi pada orang dewasa. Patofisiologi terjadinya otitis media terdiri dari berbagai faktor, yaitu: faktor individu, faktor anatomi/ fisiologi dan faktor lingkungan. Komplikasi dapat terjadi akibat OMA yang tidak diobati, pengobatan yang tidak adekuat dan adanya bakteri yang resisten terhadap antibiotik. Komplikasi intratemporal dan intrakranial akibat OMA jarang terjadi dan dapat berakibat fatal. Tujuan laporan kasus ini adalah melaporkan kasus yang jarang terjadi, yaitu: OMA dengan komplikasi intratemporal mastoiditis akut dan labirintitis akut pada orang dewasa. Dilaporkan 1 kasus OMA stadium perforasi auris sinistra pada seorang laki-laki usia 26 tahun dengan komplikasi mastoiditis akut sinistra dan labirintitis akut. Pemberian antibiotik sistemik secara empiris, analgetik-antiinflamasi, anti histamin, anti mual-muntah, antibiotik dan antiseptik topikal. Pada pasien ini tidak dilakukan tindakan operatif, karena terjadi perbaikan tanda dan gejala klinis dengan terapi medikamentosa. Diagnosis OMA dengan komplikasi intratemporal pada pasien ini tergantung pada gejala klinis yang terjadi. Mastoiditis akut sinistra ditandai dengan nyeri, bengkak dan warna kemerahan di belakang telinga kiri. Labirintitis akut ditandai dengan gangguan pendengaran pada telinga kiri, pusing berputar, mual dan muntah. Penatalaksanaan OMA dengan komplikasi intratemporal tidak selalu diperlukan tindakan operatif. Diagnosis secara dini dan pengobatan yang cepat dan tepat akan menghindarkan komplikasi yang lebih lanjut.
5
Kienitz, Tina, Marcus Quinkler, Christian J. Strasburger, and Manfred Ventz. "Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature." European Journal of Endocrinology 157, no. 1 (July 2007): 39–46. http://dx.doi.org/10.1530/eje-07-0098.
Full textAbstract:
Objective: TSH-secreting pituitary tumors (TSH-omas) are a rare cause of hyperthyroidism and account for <1% of all pituitary adenomas. Failure to recognize the presence of a TSH-oma may result in dramatic consequences such as thyroid ablation that may cause further growth in pituitary tumor. The primary goal of the treatment of TSH-omas is to remove the pituitary tumor. Medical treatment includes dopaminergic agonists or somatostatin analogs. Methods and results: We report five cases of TSH-oma diagnosed between 1997 and 2006 and review the literature. All the patients are females with an age range from 54 to 65 years at diagnosis. Four of the five patients had at least one event of thyroid surgery due to goiter or nodule of unknown dignity. Three of the five patients had a stroke before the diagnosis of TSH-oma, probably due to hypertension, or smoking and contraceptive treatment. One patient with invasive tumor growth received stereotactic radiotherapy (and developed panhypopituitarism after operation), another patient received somatostatin analogs preoperatively and successfully underwent transsphenoidal operation. Three of the five patients received dopaminergic agonists (bromocriptine 5 mg daily or cabergoline 0.5–0.75 mg per week), because they refused surgical therapy or the tumor was stable under dopaminergic therapy. All patients have been followed-up for 2.5–8 years. A normalization of circulating thyroid hormone levels was achieved in all patients. The patient who underwent operation shows no recurrence of the disease. The other patients have a stable pituitary mass without signs of growth. Conclusion: We report the successful long-term treatment of TSH-omas with different therapies.
6
Kaymak, Ebru, and Sean P. Ryder. "RNA Recognition by theCaenorhabditis elegansOocyte Maturation Determinant OMA-1." Journal of Biological Chemistry 288, no. 42 (September 6, 2013): 30463–72. http://dx.doi.org/10.1074/jbc.m113.496547.
Full text
7
Raussi, Satu, Päivi Mäntysaari, Lauri Jauhiainen, Jutta Siivonen, Leena Tuomisto, Kaisa Räsänen, and Marketta Rinne. "Lehmälle oma vai jaettu ruokintapaikka?" Suomen Maataloustieteellisen Seuran Tiedote, no. 26 (January 31, 2010): 1–7. http://dx.doi.org/10.33354/smst.75776.
Full textAbstract:
Karkearehun ruokintapaikkojen määrä on usein pihatoissa rajoitettu, eivätkä kaikki lehmät mahdu syömään samanaikaisesti. Lehmillä on kuitenkin luontainen taipumus syödä yhtä aikaa, varsinkin uuden rehun jaon jälkeen ruokintapöydällä on tungosta. Tutkimme ruokintapöytäpaikkojen rajoittamista MTT:n Minkiön pihatossa. Selvitimme myös lehmän poikimakerran ja väkirehunruokintatason nostamisen vaikutukset lehmien tuotantoon, syöntiin ja käyttäytymiseen. Kokeessamme oli 36 ayrshire-lehmää, joista 12 oli ensikoita. Lehmillä oli puolet koeajasta oma ja puolet ajasta kahden muun lehmän kesken jaettu säilörehun syöntipaikka. Jaetulla paikalla oli 1 ensikko, 1 kaksi ja 1 kolme kertaa poikinut lehmä. Kaikilla ruokintapaikoilla oli tarjolla hyvälaatuista säilörehua vapaasti. Väkirehuruokintatasoja oli kaksi; puolella lehmistä oli koko kokeen ajan rehuannoksen kuiva-aineesta 45 % ja puolella 57 % väkirehua. Väkirehu tarjottiin väkirehukioskeista sekä lypsypaikalta. Koe toteutettiin kahdessa 4 viikon jaksossa cross over-kokeena ruokintapaikkojen suhteen. Jaksolla 2 lehmät, joilla jaksolla 1 oli oma ruokintapaikka, jakoivat paikan kahden muun lehmän kanssa ja jaksolla 1 jaetulla paikalla olleet saivat omat paikat. Jaksojen viimeisillä viikoilla rekisteröitiin maitomäärä jokaiselta lypsykerralta ja maitonäytteet neljältä lypsykerralta. Eläinkohtaiset väkirehun syöntimäärät kirjautuivat automaattisesti kioskeista ja säilörehun syöntimäärät, -kerrat ja -ajat vaakakupeista. Eläinten käyttäytyminen rekisteröitiin neljänä päivänä molemmilla jaksoilla paikanpäällä tarkkaillen. Lehmiä havainnoitiin 3 kertaa 1,5 h ajan, yhteensä 36 tuntia. Lehmän sijainti kirjattiin 5 minuutin välein ja kahden lehmän välisiä sosiaalisia tapahtumia havainnoitiin jatkuvasti. Säilörehun ruokintapaikan jakaminen ei vaikuttanut lehmien säilörehun syöntimääriin eikä maitotuotoksiin, mutta vähensi hieman syöntikertoja (10,7 vs 11,3 krt/vrk; P=0,12). Säilörehun syöntiin lehmät käyttivät 141 min/vrk omalla ja 137 min/vrk jaetulla paikalla. Omalla paikalla lehmät seisoivat hieman pidempään, kuin jaetulla paikalla. Jaetun syöntipaikan lehmät käyttivät enemmän aikaa makaamiseen. Runsaampi väkirehuruokinta vähensi syödyn säilörehun määrää, syöntikertoja ja syöntipaikalla vietettyä aikaa. Vähemmän väkirehua saaneet lehmät söivät enemmän säilörehua ja seisoivat pidempään syöntipaikalla. Runsaammin väkirehua saaneet lehmät käyttivät säilörehun syönnistä vapautuneen ajan makaamiseen. Säilörehun syöntipaikan jakaminen lisäsi sosiaalisia yhteenottoja. Erityisesti ensikot olivat sosiaalisissa yhteenotoissa vanhempia lehmiä useammin aggressioita vastaanottavana osapuolena. Hyvälaatuista säilörehua vapaasti tarjottaessa syöntipaikan jakaminen kolmen lehmän kesken ei vaikuta tuotoksiin tai säilörehun syöntiin, mutta lisää lehmien välisiä sosiaalisia yhteenottoja, etenkin ensikoilla. Ruokintapaikan jakamisen vaikutukset syöntikäyttäytymiseen olivat kokeessamme vähäiset, joskin jaettu paikka hieman vähensi syöntikertoja sekä syöntipaikalla seisomista. Voimakkaampi väkirehuruokinta jätti lehmille enemmän aikaa makaamiseen. Vaakakuppipaikalla lehmä saa syödä varsin rauhassa, joten tulosten tulkinnassa on huomioitava, että kokeemme tulokset eivät ole sovellettavissa avoimeen ruokintapöytään.
8
Detwiler, Michelle R., Melanie Reuben, Xiumin Li, Eric Rogers, and Rueyling Lin. "Two Zinc Finger Proteins, OMA-1 and OMA-2, Are Redundantly Required for Oocyte Maturation in C. elegans." Developmental Cell 1, no. 2 (August 2001): 187–99. http://dx.doi.org/10.1016/s1534-5807(01)00026-0.
Full text
9
Skrzypek, Edyta, Tomasz Warzecha, Angelika Noga, Marzena Warchoł, Ilona Czyczyło-Mysza, Kinga Dziurka, Izabela Marcińska, et al. "Complex characterization of oat (Avena sativa L.) lines obtained by wide crossing with maize (Zea mays L.)." PeerJ 6 (June 25, 2018): e5107. http://dx.doi.org/10.7717/peerj.5107.
Full textAbstract:
Background The oat × maize addition (OMA) lines are used for mapping of the maize genome, the studies of centromere-specific histone (CENH3), gene expression, meiotic chromosome behavior and also for introducing maize C4 photosynthetic system to oat. The aim of our study was the identification and molecular-cytogenetic characterization of oat × maize hybrids. Methods Oat DH lines and oat × maize hybrids were obtained using the wide crossing of Avena sativa L. with Zea mays L. The plants identified as having a Grande-1 retrotransposon fragment, which produced seeds, were used for genomic in situ hybridization (GISH). Results A total of 138 oat lines obtained by crossing of 2,314 oat plants from 80 genotypes with maize cv. Waza were tested for the presence of maize chromosomes. The presence of maize chromatin was indicated in 66 lines by amplification of the PCR product (500 bp) generated using primers specific for the maize retrotransposon Grande-1. Genomic in situ hybridization (GISH) detected whole maize chromosomes in eight lines (40%). All of the analyzed plants possessed full complement of oat chromosomes. The number of maize chromosomes differed between the OMA lines. Four OMA lines possessed two maize chromosomes similar in size, three OMA—one maize chromosome, and one OMA—four maize chromosomes. In most of the lines, the detected chromosomes were labeled uniformly. The presence of six 45S rDNA loci was detected in oat chromosomes, but none of the added maize chromosomes in any of the lines carried 45S rDNA locus. Twenty of the analyzed lines did not possess whole maize chromosomes, but the introgression of maize chromatin in the oat chromosomes. Five of 66 hybrids were shorter in height, grassy type without panicles. Twenty-seven OMA lines were fertile and produced seeds ranging in number from 1–102 (in total 613). Sixty-three fertile DH lines, out of 72 which did not have an addition of maize chromosomes or chromatin, produced seeds in the range of 1–343 (in total 3,758). Obtained DH and OMA lines were fertile and produced seeds. Discussion In wide hybridization of oat with maize, the complete or incomplete chromosomes elimination of maize occur. Hybrids of oat and maize had a complete set of oat chromosomes without maize chromosomes, and a complete set of oat chromosomes with one to four retained maize chromosomes.
10
Zheng, Jie, Xue Min Jiao, Ting Yang, and Yong He. "Research on Synthesis Processing of Microcapsule Wall Material with Emulsion Crosslinking Method." Advanced Materials Research 236-238 (May 2011): 2246–49. http://dx.doi.org/10.4028/www.scientific.net/amr.236-238.2246.
Full textAbstract:
In this study, the microcapsule was prepared by emulsion crosslinking method, using trisodium trimetaphosphate (TSTP) as crosslinking agent. The microcapsule was named OMA-MPs because the mixture of Octenyl succinic starch ester(OSA-starch)，maltodextrin starch and arabic gum were used as raw material. Orthogonal experiment was used in this work to find the relationship between the small diameter of OMA - MPs and preparation factors. The better condition is that the small diameter of OMA-MPs technique was that the stirring rate 400 rpm, the materials concentration 15%, the crosslinking agent concentration 1%, and the volume ratios(w2/w1) 120:100. Due to the processing route without the use of toxic organic solvents, it is expected that these microparticles can be used as delivery vehicles for controlled release of food and drug.
11
Lee, Donna, Lakshmi Mahali, and Vafa Tabatabaie. "Successful Multimodal Treatment of a TSH-Secreting Pituitary Adenoma (TSH-oma)." Journal of the Endocrine Society 5, Supplement_1 (May 1, 2021): A611—A612. http://dx.doi.org/10.1210/jendso/bvab048.1247.
Full textAbstract:
Abstract Background: TSH-omas are rare tumors accounting for 0.5-2% of all pituitary adenomas. Due to their indolent nature, most TSH-omas are diagnosed at the stage of invasive macroadenomas. Over the past several decades, the management of TSH-omas has evolved substantially. While surgery remains first-line therapy, somatostatin analogs have emerged as important therapeutic agents as a result of their effectiveness in normalizing thyroid hormone levels in ~95% of patients with severe hyperthyroidism and reducing TSH-oma size in ~50% of patients. Clinical Case: A 52-year-old woman with a history of multinodular goiter was incidentally found to have a 2.2 x 1.8 x 2.1 cm pituitary macroadenoma with suprasellar extension, mass effect on the optic chiasm, and left cavernous sinus involvement when she presented with chest pain, palpitations, headache, and left-sided numbness and weakness. Laboratory results showed high FT4/T4/T3 with inappropriately high TSH, elevated α-subunit, and low cortisol with low-normal ACTH highly suggestive of TSH-oma with concurrent secondary adrenal insufficiency. An ophthalmology exam revealed a left superior temporal defect. The patient was treated with atenolol, prednisone, and octreotide two weeks before surgery with symptomatic improvement and near-normalization of FT4. Following an uncomplicated transsphenoidal resection, FT4 normalized within one week. At her one-month follow-up, both TSH and FT4 were normal, and her secondary adrenal insufficiency had resolved. Her visual field defect also recovered. Laboratory Results: TSH 5.35 (normal range 0.40-4.60 μU/mL), FT4 3.0 (0.8-1.7 ng/dL), T4 18.1 (5.0-12.0 μg/dL), T3 235 (80-200 ng/dL), ACTH 10 (6-50 pg/mL), cortisol 4.5 (5.0-25.0 μg/dL), α-subunit 8.0 (0.1-1.5 ng/mL); after 2 weeks on SQ octreotide 50mg q12h: TSH 1.93 (0.30-4.20 μU/mL), FT4 1.7 (0.6-1.5 ng/dL); 1 month post-op: TSH 1.53 (0.30-4.20 μU/mL), FT4 0.8 (0.6-1.5 ng/dL), ACTH 12 (7.2-63 pg/mL), cortisol 6.9 (4.0-20.0 μg/dL) Conclusion: Since the first reported case of TSH-oma in 1960, the diagnostic and therapeutic management of these rare pituitary adenomas have evolved due to the emergence of ultrasensitive TSH assays, advanced imaging and surgical techniques, and somatostatin analogs. However, to this day, most TSH-omas are still diagnosed at the stage of invasive macroadenomas, when successful surgical resection becomes more difficult. Hence, up to two-thirds of patients may require adjuvant therapy with medication or radiation. As evidenced in our patient, who achieved a near-euthyroid state within just two weeks of starting low dose octreotide, somatostatin analogs are highly effective in controlling hyperthyroidism and have solidified their place in the therapeutic management of TSH-omas. This case highlights the success of a multimodal approach to the treatment of TSH-omas.
12
Gilbert, B., D. Courvoisier, D. Mongin, K. Lauper, C. Perrier, R. Muller, and A. Finckh. "POS0668 REAL WORLD EFFECTIVENESS OF BARICITINIB IN THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA)." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 577–78. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1781.
Full textAbstract:
Background:When not responding to conventional synthetic DMARDs (csDMARDs), rheumatoid arthritis (RA) patients may receive biological DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs) including baricitinib (BARI). While BARI has demonstrated efficacy in randomized controlled trials, limited studies have established comparative effectiveness in real world settings, in particular when used in b/tsDMARD-naïve patients.Objectives:To analyze the effectiveness of BARI versus alternative bDMARDs, as assessed by drug maintenance over time and by response rates at 12 months.Methods:This is a nested study of RA patients, within the prospective Swiss Clinical Quality Management (SCQM) observational cohort.All treatment courses (TC) with BARI or alternative bDMARDs initiated between 2017-09-01 and 2020-06-01, with at least one follow-up visit, were included. TC with BARI were compared to TC with alternative bDMARDs (non-BARI), including all b/tsDMARDs except rituximab. The non-BARI group was then subdivided into TNF inhibitors (TNFi) and other mode of action bDMARDs (OMA), excluding tsDMARDs. A secondary analysis focusing specifically on b/tsDMARD naïve patients was conducted.Baseline characteristics were compared using ANOVA or χ2 tests. A Cox-model survival analysis assessed drug maintenance. 12-month response rates were estimated using an attrition-corrected, confounder-adjusted approach (1). CDAI score ≤10 defined low disease activity state (LDA), and CDAI score ≤2.8 defined remission.Results:Overall, 1218 eligible TC (from 1028 patients) were initiated during the study period (273 in BARI, 154 other tsDMARD, 473 in TNFi and 318 in OMA). Drug maintenance was significantly shorter for TNFi compared to BARI, even after adjustment for potential confounders (Hazard ratio (HR) for drug discontinuation 1.85 (95% CI [1,40 – 2,43]); p < 0.001). Drug maintenance was also numerically shorter for the OMA group compared to BARI, but the difference was not significant (HR 1.18 (95% CI [0.87 – 1.60]); p = 0.28). These differences were larger when analysing only bDMARD-naïve patients (Figure 1a).All TC taken together, the rates of LDA and remission did not differ significantly between the 3 groups at 12 months. LDA ranged from 63% to 67% (BARI vs OMA p = 0.87; BARI vs TNFi p = 0.81) and remission from 19% to 23% (BARI vs OMA p = 0.30; BARI vs TNFi p = 0.77; Figure 1b).Conclusion:BARI demonstrated a significantly higher overall drug maintenance than TNFi, and a similar drug maintenance to OMA, both in a bDMARD-naïve population and in the overall population. The adjusted 12-month response rates did not differ between BARI, TNFi and OMA groups. These results suggest that prescription of BARI after csDMARD has at least similar outcomes as alternative bDMARDs.References:[1]Lauper, K., et al. Sat0588. Annals of the Rheumatic Diseases 78 (2019).Table 1.Baseline characteristics of studied populationVariableOverall comparison:BARI vs non-BARISubgroup analysis 1:by bDMARD type (tsDMARD excluded)Subgroup analysis 2:In b/tsDMARD-naïve patientsBARI(TC = 273; 273 patients)Non-BARI(altogether)(TC = 945; 755 patients)p valuesTNFi(TC = 473; 408 patients)OMA(TC = 318; 298 patients)p values(vs BARI)BARI(n = 46)TNFi(n = 225)OMA(n = 65)p valuesMean (SD)Otherwise: n %Mean (SD)Otherwise: n %Mean (SD)Otherwise: n %Concomitant csDMARD41 %46 %0.1754 %41 %<0.0150 %61 %48 %0.1Line of Therapy-1st (= bio-naive)17 %35 %<0.0148 %20 %<0.01100 %100 %100 %-2nd20 %23 %23 %23 %-3rd19 %16 %11 %24 %-4th or later44 %26 %18 %33 %Female78%74 %<0.2174 %73 %0.2870 %71 %74 %0.88Age59 (14)56 (14)0.0152 (15)58 (13)<0.0157 (15)51 (14)57 (16)<0.01Disease duration (years)13 (10)10 (9)<0.018 (9)11 (9)<0.015.5 (6.45)5 (7)6.5 (9)0.243CDAI baseline15 (9)15 (10)0.914 (9)16 (11)0.0513 (7)14 (9)14 (10)0.72Previous tsDMARD (non-BARI)33 %8 %<0.014 %11 %<0.010 %0 %0 %TC duration > 12-months37 %29 %0.0127 %30 %0.0237 %29 %34 %0.52BARI = baricitinib, TNFi = TNF inhibitors, OMA = other mode of action, Non-BARI = TNFi + OMA + other tsDMARDs, SD = standard deviation.Disclosure of Interests:Benoit GILBERT: None declared, Delphine Courvoisier: None declared, Denis Mongin: None declared, Kim Lauper Consultant of: Gilead Galapagos, Grant/research support from: AbbVie, Clementine Perrier Shareholder of: Eli Lilly, Employee of: Eli Lilly, Rudiger Muller Consultant of: AbbVie, Novartis, Grant/research support from: GEBRO Pharma, Axel Finckh Speakers bureau: AbbVie, BMS, Pfizer, Eli-Lilly, Consultant of: AbbVie, BMS, Pfizer, Eli-Lilly, Grant/research support from: BMS, Pfizer, Eli-Lilly
13
Dylus, David, Yannis Nevers, Adrian M. Altenhoff, Antoine Gürtler, Christophe Dessimoz, and Natasha M. Glover. "How to build phylogenetic species trees with OMA." F1000Research 9 (June 4, 2020): 511. http://dx.doi.org/10.12688/f1000research.23790.1.
Full textAbstract:
Knowledge of species phylogeny is critical to many fields of biology. In an era of genome data availability, the most common way to make a phylogenetic species tree is by using multiple protein-coding genes, conserved in multiple species. This methodology is composed of several steps: orthology inference, multiple sequence alignment and inference of the phylogeny with dedicated tools. This can be a difficult task, and orthology inference, in particular, is usually computationally intensive and error prone if done ad hoc. This tutorial provides protocols to make use of OMA Orthologous Groups, a set of genes all orthologous to each other, to infer a phylogenetic species tree. It is designed to be user-friendly and computationally inexpensive, by providing two options: (1) Using only precomputed groups with species available on the OMA Browser, or (2) Computing orthologs using OMA Standalone for additional species, with the option of using precomputed orthology relations for those present in OMA. A protocol for downstream analyses is provided as well, including creating a supermatrix, tree inference, and visualization. All protocols use publicly available software, and we provide scripts and code snippets to facilitate data handling. The protocols are accompanied with practical examples.
14
Akard, Luke Paul, Hagop M. Kantarjian, Franck E. Nicolini, Meir Wetzler, Jeffrey Howard Lipton, Michele Baccarani, Hanna Jean Khoury, Adam Craig, and Jorge E. Cortes. "Omacetaxine mepesuccinate in chronic phase chronic myeloid leukemia (CML-CP): A post hoc analysis of myelosuppression." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 7073. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.7073.
Full textAbstract:
7073 Background: Omacetaxine mepesuccinate (OMA) was active in 2 CML trials of patients with T315I Bcr-Abl mutations or failing ≥2 tyrosine kinase inhibitors. Methods: Hematologic events/recovery were pooled from the 2 trials. OMA 1.25 mg/m2BID was given in 28-day cycles: ≤14 days induction, ≤7 days maintenance with dose delay/change as needed. Results: Of 108 patients, median exposure was 7.4 mos, with a median 3 cycle delays and 9 days dosing per patient. Of 91 patients receiving ≥2 cycles, 79 (87%) had ≥1 delay (366 delays in 729 cycles), most due to grade ≥3 thrombocytopenia. Median delay was longest early—peaking at 25 days in cycle 3. Predefined hematologic nadirs (see Table) were reached mostly in initial cycles and less after dose adjustments; 80 patients received blood products, 10 antibiotics. Most common lab grade 3/4 hematologic toxicities were thrombocytopenia (85%), neutropenia (81%), and anemia (62%). Grade 3/4 adverse events included 12 infections (6 treatment related, including 1 pneumonia, 1 sepsis) and 7 hemorrhages (1 related conjunctival, 1 postprocedural, 2 cerebral, 3 gastrointestinal [1 related]); 38 events were fatal (related: 1 pancytopenia, 2 sepsis, 2 unknown). There were 11 hematologic hospitalizations. Conclusions: In heavily pretreated CML-CP, myelosuppression was most common after initial OMA cycles, improved with dose adjustments, and rarely led to severe outcomes. Support: Teva BPP R&D, Inc. Clinical trial information: NCT00375219, NCT00462943. [Table: see text]
15
Rojas Acuña, Joel, Jorge A. Bravo Cabrejos, and Naoshi Fukushima. "Corrientes Eléctricas Alineadas con el Campo Geomagnético en Bajas Latitudes Magnéticas." Revista de Investigación de Física 2, no. 01-02 (July 30, 1999): 1–8. http://dx.doi.org/10.15381/rif.v2i01.8565.
Full textAbstract:
La existencia de las corrientes eléctricas alineadas con el campo geomagnético en bajas latitudes magnéticas del Perú ha sido inferida utilizando los métodos de Gettemy[1] y Fukushima[2] aplicados a los datos magnéticos registrados durante el Año Geofísico Internacional (AGI) y el Año Internacional del Electrochorro Ecuatorial (AIEE) en el Perú. La representación de la variación magnética diaria quieta solar, Sq, usando mapas de contorno magnéticos de las componentes D, H y Z del campo geomagnético registrado en el Observatorio Magnético de Huancayo (OMH) para los dos periodos (1957-1958 y 1990-1991) permite visualizar los cambios estacionales en la variación diaria. Los resultados obtenidos son similares a los obtenidos por Gettemy para el Observatorio Magnético de Koror (OMK) en las Islas Palau (Océano Pacifico) durante el AGI. Los mapas de contorno magnéticos para las componentes D, H y Z del campo geomagnético registrado en el Observatorio Magnético de Ancón (OMA) para el periodo de 1990-1991 son también muy similares a los de Huancayo y Koror, aún en épocas diferentes. Asimismo, los mapas de contorno magnéticos para otras cinco estaciones magnéticas cerca al Ecuador magnético (1958) han sido elaborados para fines de comparación e interpretación. Dos diagramas, referidos a los patrones del sistema de corrientes eléctricas superiores de la variación magnética diaria quieta solar, Sq, para 1/2(verano + invierno) y 1/2(verano - invierno) en bajas latitudes magnéticas del Perú, fueron elaborados utilizando el método de análisis de las variaciones magnéticas diarias en tierra propuesto por Fukushima [2] para medianas latitudes geomagnéticas aplicado a cuatro estaciones magnéticas del Japón. Los resultados obtenidos nos permiten inferir las corrientes eléctricas alineadas con el campo geomagnético en bajas latitudes y confirmar la inversión estacional en la variación magnética diaria de la declinación en el OMH y en el OMA.
16
Zhang, Kuan, Huihui Li, and Zhiyin Song. "Membrane depolarization activates the mitochondrial protease OMA 1 by stimulating self‐cleavage." EMBO reports 15, no. 5 (April 9, 2014): 576–85. http://dx.doi.org/10.1002/embr.201338240.
Full text
17
Matitaputty, Jenny Koce, and Ida Masinay. "The Ceremonial Procession and Meaning of Makan Patita in Negeri Oma - Maluku." Society 8, no. 2 (July 31, 2020): 298–312. http://dx.doi.org/10.33019/society.v8i2.181.
Full textAbstract:
Makan Patita is a tradition of communal feasting or eating together among Maluku communities that practiced in festivity the Panas Pela, Panas Gandong, King coronation, building Baileo house, the celebration of city`s anniversary day, and other events in Ambon city. However, for the people of Negeri Oma in Haruku Island, the tradition of Makan Patita differs from others. The differences are attracted to be discussed about the ceremonial procession and its meaning of the tradition of Makan Patita in Negeri Oma. This research aims to describe the ceremonial process and its meaning of the Makan Patita Soa practiced in Negeri Oma, Haruku Island District, Central Maluku Regency, Maluku Province, Indonesia. This is a qualitative research where the data source obtained purposively and the data collection techniques by using observation, interview, and documentation. The results showed that: 1) Makan Patita in Negeri Oma is divided into two types; first, the uncle feeds his nephew/child (Mara/Marei), and also the nephew/child feeds his uncle (ana kas makang om). There are three stages in the practice of Makan Patita tradition; the initial stage, a time-set meeting, and preparation of various things, both food and a long white table and the prayers of struggle in Baileo Kotayasa by the Bapa Lima-Lima. In the second stage, the Makan Patita begins with Cakelele dances and the ceremonial procession takes children to the Patita dining table, then the uncles feed their nephews. In the final stage, each remaining food must be brought back and eaten by all children at home, then covered with a Eucharistic prayer for the Soa and Maradansa. 2) The meaning of Makan Patita tradition for the people in Negeri Oma is kinship ties, respect, and appreciation for elders (uncles) and it contains the symbolic meaning of hope to the children in the Soa will become a good generation and remain in the fellowship of siblings.
18
Joshi, Shantaram S., Joanne M. Deboer, Sarah J. Strandjord, Samuel J. Pirruccello, Warren G. Sanger, Dennis D. Weisenburger, and J. Graham Sharp. "Characterization of a newly established human burkitt's lymphoma cell line, OMA-BL-1." International Journal of Cancer 47, no. 5 (March 12, 1991): 643–48. http://dx.doi.org/10.1002/ijc.2910470502.
Full text
19
Pirruccello, SJ, JD Jackson, MS Lang, J. DeBoer, S. Mann, D. Crouse, WP Vaughan, KA Dicke, and JG Sharp. "OMA-AML-1: a leukemic myeloid cell line with CD34+ progenitor and CD15+ spontaneously differentiating cell compartments." Blood 80, no. 4 (August 15, 1992): 1026–32. http://dx.doi.org/10.1182/blood.v80.4.1026.1026.
Full textAbstract:
Abstract OMA-AML-1 was established from a patient with acute myelomonocytic (M4) leukemia at fifth relapse when blasts were greater than 85% CD34+, CD15- . Leukemic cells were established in suspension culture and independently grown as subcutaneous tumors in SCID mice. Cells growing in suspension culture underwent differentiation by phenotypic and morphologic criteria. In contrast, cells grown as subcutaneous solid tumors in SCID mice maintained progenitor cell characteristics with high-density CD34 expression and lack of morphologic differentiation. A tendency toward differentiation to CD15+, CD34- cells in vitro and self- renewal of CD34+, CD15- cells in vivo was consistently demonstrated regardless of whether cells were initially grown in vitro or in vivo. The cell line maintains both a CD34+, CD15- progentitor cell pool and a non-overlapping, CD15+, CD34- differentiating cell compartment after more than 1 year in continuous culture. Cell cycle analysis and cloning experiments were consistent with terminal differentiation occurring in the CD15+, CD34- population. The cell line shows concentration- dependent proliferative responses to interleukin (IL)-3, granulocyte- macrophage colony-stimulating factor (GM-CSF), and IL-6, but not to granulocyte CSF (G-CSF). OMA-AML-1 appears to mimic several features of normal myeloid hematopoiesis and should prove useful for the study of normal and malignant myeloid differentiation.
20
Pirruccello, SJ, JD Jackson, MS Lang, J. DeBoer, S. Mann, D. Crouse, WP Vaughan, KA Dicke, and JG Sharp. "OMA-AML-1: a leukemic myeloid cell line with CD34+ progenitor and CD15+ spontaneously differentiating cell compartments." Blood 80, no. 4 (August 15, 1992): 1026–32. http://dx.doi.org/10.1182/blood.v80.4.1026.bloodjournal8041026.
Full textAbstract:
OMA-AML-1 was established from a patient with acute myelomonocytic (M4) leukemia at fifth relapse when blasts were greater than 85% CD34+, CD15- . Leukemic cells were established in suspension culture and independently grown as subcutaneous tumors in SCID mice. Cells growing in suspension culture underwent differentiation by phenotypic and morphologic criteria. In contrast, cells grown as subcutaneous solid tumors in SCID mice maintained progenitor cell characteristics with high-density CD34 expression and lack of morphologic differentiation. A tendency toward differentiation to CD15+, CD34- cells in vitro and self- renewal of CD34+, CD15- cells in vivo was consistently demonstrated regardless of whether cells were initially grown in vitro or in vivo. The cell line maintains both a CD34+, CD15- progentitor cell pool and a non-overlapping, CD15+, CD34- differentiating cell compartment after more than 1 year in continuous culture. Cell cycle analysis and cloning experiments were consistent with terminal differentiation occurring in the CD15+, CD34- population. The cell line shows concentration- dependent proliferative responses to interleukin (IL)-3, granulocyte- macrophage colony-stimulating factor (GM-CSF), and IL-6, but not to granulocyte CSF (G-CSF). OMA-AML-1 appears to mimic several features of normal myeloid hematopoiesis and should prove useful for the study of normal and malignant myeloid differentiation.
21
Pirruccello, Samuel J., John D. Jackson, and J. Graham Sharp. "The Leukemic Myeloid Cell Line OMA-AML-1: AnIn VitroModel of Hematopoietic Cell Differentiation." Leukemia & Lymphoma 13, no. 1-2 (January 1994): 169–78. http://dx.doi.org/10.3109/10428199409051668.
Full text
22
Rea, Delphine, Hagop M. Kantarjian, Meir Wetzler, Franck E. Nicolini, Jeffrey H. Lipton, Luke Paul Akard, Hanna Jean Khoury, et al. "Post hoc analysis of sustained efficacy/tolerability of ≥12 cycles of omacetaxine mepesuccinate in chronic myeloid leukemia (CML)." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 7066. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.7066.
Full textAbstract:
7066 Background: Subcutaneous omacetaxine mepesuccinate (OMA), a first-in-class cephalotaxine, inhibits protein synthesis independent of Bcr-Abl signaling. It showed clinical activity in 2 phase II, open-label CML trials, 1 in patients with a T315I Bcr-Abl mutation failing imatinib, and 1 in patients failing ≥2 tyrosine kinase inhibitors (TKIs). Methods: This post hoc analysis pooled patients with chronic phase (CP) or accelerated phase (AP) from the 2 trials. 28-day cycles of OMA 1.25 mg/m2BID were given ≤14 days for induction, ≤7 days as maintenance with dose delay/change as needed. Primary endpoints were major cytogenetic response (MCyR) for CP and complete hematologic response (CHR) for AP. Adverse events (AEs) were assessed. Results: Of 108 CP and 51 AP patients from the 2 trials, 31 (29%) CP and 7 (14%) AP patients received ≥12 cycles (Table). At baseline in the ≥12-cycle groups, most CP (median age 59 y) and AP patients (median age 67 y) had received hydroxyurea (17/31, 4/7) and ≥2 TKIs (22/31, 5/7), were not in CHR (22/31, 5/7), and were T315I positive (23/31, 3/7). As of March 31, 2012, 9 CP and 2 AP patients continued OMA treatment. Overall, mean days dosed per cycle were 6.1 for CP, 9.7 for AP; 5.3 and 8.9 at cycle 12. Grade 3/4 AEs occurred in 35/38 patients in this post hoc analysis, most in early cycles; 15/31 CP, 2/7 AP had grade ≥3 AEs first occurring at ≥12 cycles. Across all cycles, most common grade ≥3 AEs were thrombocytopenia (24/31 CP, 5/7 AP), anemia (16/31, 7/7), and neutropenia (17/31, 3/7).Nine patients receiving ≥12 cycles (5/31, 4/7) discontinued, most commonly due to disease progression (n=2). Conclusions: In this post hoc analysis of heavily pretreated CML-CP and CML-AP patients who had failed prior TKI therapy, efficacy was often durable for those who received OMA for ≥12 cycles. Most grade 3/4 AEs were hematologic and declined with time. Support: Teva BPP R and D, Inc. Clinical trial information: NCT00375219, NCT00462943.
23
Gilbert, B., K. Lauper, D. Courvoisier, C. Perrier, R. Muller, and A. Finckh. "THU0203 REAL WORLD EFFECTIVENESS OF BARICITINIB IN THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA)." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 325–26. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1243.
Full textAbstract:
Background:Patients with rheumatoid arthritis (RA) intolerant or not responding adequately to conventional synthetic DMARD (csDMARD) usually receive biological DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs) as 2ndline. Baricitinib (BARI), a once-daily oral selective Janus kinase inhibitor, is efficient in randomised controlled trials but still lacks evidence for effectiveness in real world settings.Objectives:To characterise patients initiating treatment with BARI or other alternative bDMARDs, and to perform an analysis of drug maintenance.Methods:This is an observational, prospective, cohort study, within the Swiss Clinical Quality Management (SCQM) register.All treatment courses (TC) initiated between 2017-09-01 and 2019-10-01 were considered, comparing TC with BARI (BARI group) to TC with alternative bDMARDs, either TNF inhibitors (TNFi group) or other mode of action bDMARDs (OMA group), excluding rituximab.Baseline characteristics were compared using ANOVA or χ2 tests. The crude drug maintenance was assessed by survival analysis (Kaplan-Meier). To correct for potential confounding factors, a Cox proportional hazard model was used. Missing values were imputed using multiple imputation with chained equations.Results:During the study period, 979 TC were initiated (240 in BARI group, 461 in TNFi group and 278 in OMA group). BARI was prescribed to significantly older patients, with longer disease durations and more previous treatment failures (Table 1). Unadjusted drug maintenance was significantly shorter in the TNFi compared to the BARI group (log rank p = 0.019). After adjustment for potential confounding factors, the hazard of TNFi discontinuation remained higher than for BARI (Hazard Ratio (HR) 1.48 (95% CI = [1.05 – 2.09]; p = 0.02)). A similar trend was observed when comparing the OMA drugs to BARI, with a HR for discontinuation of 1.42 (95% CI = [0.98 – 2.05]; p = 0.06) (Figure 2). Covariates significantly associated with decreased drug maintenance were concomitant csDMARD and concomitant glucocorticoids (Figure 2).Table 1.Baseline characteristics of studied populationVariableCategoriesBaricitinib(TC = 240; 240 patients)Mean (SD)Otherwise: n %TNFi(TC = 461; 397 patients)Mean (SD)Otherwise: n %OMA bDMARDs(TC = 278; 253 patients)Mean (SD)Otherwise: n %P valuesConcomitant csDMARD at baseline45 %54 %46 %0.02Line of Therapy1st20 %46 %22 %<0.012nd22 %25 %26 %3rd14 %14 %26 %4thor later43 %16 %27 %Gender (female)80 %71 %74 %0.05Age59 (13)53 (14)59 (13)<0.01Seropositivity (ACPA and/or RF)75 %71 %79 %0.04HAQ-DI Score0.9 (0.7)0.7 (0.6)0.8 (0.6)0.02Disease duration (years)12 (10)9 (10)11 (9)<0.01CDAI baseline19 (10)15 (12)19 (14)0.09LegendTC = Treatment Courses. SD = Standard Deviation. TNFi = TNF inhibitors. OMA bDMARDs = Other Mode of Action biological DMARDs. csDMARD = conventional synthetic DMARD. ACPA = Anti Citrullinated Peptide Antibodies. RF = Rheumatoid Factor. HAQ-DI= Health Assessment Questionnaire Disability Index. CDAI = Clinical Disease Activity Index.Conclusion:In this preliminary analysis, baricitinib was prescribed to older patients, with longer disease durations, and more previous treatment failures compared to alternative bDMARDs. Baricitinib demonstrated a significantly higher drug maintenance than TNFi, while similar trend was observed in comparison to OMA drugs.Conflict of interest:This analysis has been made possible by financial support of Eli Lilly (Suisse) SA to the Geneva University Hospitals (HUG).Disclosure of Interests: :Benoit GILBERT: None declared, Kim Lauper: None declared, Delphine Courvoisier: None declared, Clementine Perrier Shareholder of: Share of Eli Lilly Company, Employee of: I am currently an employee of Eli Lilly Suisse SA, Rudiger Muller Consultant of: AbbVie, Nordic, Sandoz, Axel Finckh Grant/research support from: Pfizer: Unrestricted research grant, Eli-Lilly: Unrestricted research grant, Consultant of: Sanofi, AB2BIO, Abbvie, Pfizer, MSD, Speakers bureau: Sanofi, Pfizer, Roche, Thermo Fisher Scientific
24
Guven-Ozkan, T., S. M. Robertson, Y. Nishi, and R. Lin. "zif-1 translational repression defines a second, mutually exclusive OMA function in germline transcriptional repression." Development 137, no. 20 (September 8, 2010): 3373–82. http://dx.doi.org/10.1242/dev.055327.
Full text
25
Grill, Sabine, Maryam Yahiaoui-Doktor, Maryam Basrai, Joachim Struck, Janin Schulte, Anika Berling-Ernst, Christoph Engel, et al. "Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers." Breast Cancer Research and Treatment 186, no. 3 (February 4, 2021): 741–52. http://dx.doi.org/10.1007/s10549-020-06070-x.
Full textAbstract:
AbstractBackgroundGermlineBRCA1/2mutation carriers (gBMC) face increased cancer risks that are modulated via non-genetic lifestyle factors whose underlying molecular mechanisms are unknown. The peptides Neurotensin (NT) and Enkephalin (ENK)—involved in tumorigenesis and obesity-related diseases—are of interest. We wanted to know whether these biomarkers differ between gBMC and women from the general population and what effect a 1-year lifestyle-intervention has in gBMC.MethodsThe stable precursor fragments pro-NT and pro-ENK were measured at study entry (SE), after 3 and 12 months for 68 women from LIBRE-1 (a controlled lifestyle-intervention feasibility trial for gBMC involving structured endurance training and the Mediterranean Diet). The SE values were compared with a cohort of the general population including female subjects with and without previous cancer disease, non-suggestive for hereditary breast and ovarian cancer (OMA-reference). For LIBRE-1, we analysed the association between the intervention-related change in the two biomarkers and certain lifestyle factors.ResultsAt SE, gBMC had a higher median pro-NT than OMA-reference (in the subgroups with previous cancer 117 vs. 91 pmol/L,p = 0.002). Non-diseased gBMC had lower median pro-ENK levels when compared to the non-diseased reference group. VO2peak and pro-NT 1-year change in LIBRE-1 were inversely correlated (r = − 0.435; CI − 0.653 to − 0.151;p = 0.004). Pro-ENK correlated positively with VO2peak at SE (r = 0.323; CI 0.061–0.544;p = 0.017). Regression analyses showed an inverse association of 1-year changes for pro-NT and Omega-6/Omega-3 (Estimate: − 37.9,p = 0.097/0.080) in multivariate analysis.ConclusionOur results give first indications for lifestyle-related modification particularly of pro-NT in gBMC.
26
Butragueño Díaz Guerra, Belén, Javier Fco Raposo Grau, and Maria Asunción Salgado de la Rosa. "On how communication transforms architectural perception. Seattle Library, OMA = De cómo la comunicación trasforma la percepción de la arquitectura. Biblioteca de Seattle, OMA." Advances in Building Education 4, no. 1 (June 8, 2020): 57. http://dx.doi.org/10.20868/abe.2020.1.4416.
Full textAbstract:
ABSTRACTMultiple communicative strategies can be followed in architecture according to the target audience. The mechanisms of representation may radically vary when the recipient is the client, the constructor, the curator, a colleague or even an instructor (1). As an example, the approach may be mainly visual when the target is the client. However, it may be strictly conceptual when pointing to the jury members in a competition. In certain cases, the adaptation of the graphic language to the different scenarios leads to such a distortion on the message that the original project is hardly recognizable. This article will focus on the project of the Public Seattle Library, designed by the architect Rem Koolhaas. The analysis of five different communicative strategies of the project show peculiar and unequal graphic narrations: from the concept book of the competition, the website of LMN (the American partners of Rem Koolhaas- OMA in this particular project), the website of OMA, the coverage on the Seattle press, the Library Brochure for teenagers and the approach developed on the "Content" book. Rem Koolhaas coined the concept of "design of information" to express the fundamental relationship between the message and media in architecture. In his practice, the communicative strategy is present from the beginning of the design process till the final stages. In this article, the thoughtful comparison of these examples will enable to extract conclusions on the use of communication in architectural design and reflect on the iconic and communicative dimension of architecture in general.RESUMENEn arquitectura, se pueden seguir múltiples estrategias comunicativas en función de la audiencia a la que estén dirigidas. Los mecanismos de representación varían radicalmente cuando el receptor es un cliente, el constructor, un comisario expositivo, un colega arquitecto o un profesor. Como ejemplo, se adoptaría una aproximación fundamentalmente visual en el caso de dirigirnos a un cliente, mientras que para una comunicación en un concurso, se optaría por una aproximación netamente conceptual. En determinados casos, la adaptación del lenguaje gráfico a los distintos escenarios genera tal distorsión en el mensaje que el proyecto original resulta prácticamente irreconocible. El artículo se centra en el proyecto de la Biblioteca Pública de Seattle, diseñado por Rem Koolhaas. El análisis de cinco estrategias comunicativas distintas nos muestra narraciones gráficas casi antagónicas. Desde la propuesta del concurso, la web de LMN (los socios americanos de OMA), pasando por la propia web de OMA, la cobertura en prensa o el folleto informativo de la propia biblioteca, Rem Koolhaas muestra la especial relación entre el mensaje y el medio en arquitectura, acuñando el término “diseño de la información”. En su trabajo, la estrategia comunicativa se encuentra presente desde el inicio del proceso de diseño y hasta los estadios finales. Mediante la comparación analítica de los distintos ejemplos se podrán extraer conclusiones del uso de la comunicación en el diseño arquitectónico y su reflejo en la dimensión icónica de la arquitectura.
27
Elsheikh, Arwa Mahmoud, G. Edward Vates, and Ismat Shafiq. "A Rare Case of Thyrotropin Secreting Pituitary Macroadenoma Primarily Treated With Somatostatin Analogue." Journal of the Endocrine Society 5, Supplement_1 (May 1, 2021): A568. http://dx.doi.org/10.1210/jendso/bvab048.1158.
Full textAbstract:
Abstract Introduction/Background: Thyrotropin secreting pituitary adenomas (TSH-oma) are a rare cause of hyperthyroidism. They account for <1% of the cases of hyperthyroidism with a reported incidence of 2.8 per 1 million in Sweden. Diagnosis is suspected by the presence of elevated T4 and T3 in the setting of an unsuppressed TSH level. The presence of large pituitary adenoma is highly suggestive of the diagnosis and can be differentiated from thyroid hormone resistance by elevated alpha subunit and SHBG levels. Trans-sphenoidal surgery is the definitive treatment. Peri-operative medical treatment with somatostatin analogues is indicated to achieve euthyroidism and prevent surgical risks and thyroid storm. The use of somatostatin analogues as a primary treatment for TSH-oma is still under investigation. We hereby report a rare case of TSH-oma where somatostatin analogues successfully resulted in normalization of thyroid function and tumor size reduction. Clinical Case: A 61 years old gentleman with a history of hypothyroidism diagnosed three years before presentation to the Pituitary clinic. He was treated with Levothyroxine. On clinical examination, he had mild tremor and warm sweaty palms with no stigmata of Grave’s disease. The thyroid function test showed elevated free T4 of 3.6 ng/dl (0.9-1.7), elevated free T3 of 8.6 pg/ml (2.0-4.4), and a high TSH level of 9.10 μIU/ml (0.27-4.20). His prolactin level was mildly elevated at 24.8 ng/ml(4.0-15.2). Testosterone, IGF-1, and cortisol levels were normal. An MRI of his pituitary gland showed large pituitary macroadenoma with supra-sellar extension and mild compression of the optic nerve. He had an elevated alpha subunit of 5.6 ng/ml (<1.37) and a high SHBG level of 198 nmol/l(10-80). TSH adenoma was diagnosed and he was planned for trans-sphenoidal surgery. Pre-operative treatment with somatostatin analogue Lanerotide 90 mg monthly injection was initiated. Interestingly normal thyroid function was observed approximately 1 month after his first injection. Repeat MRI showed a considerable decrease in the size of the pituitary macroadenoma. The patient opted to hold on to surgery and to continue on medical treatment. His thyroid function remains normal 15 months after initiation of treatment and his MRI continues to show stable pituitary adenoma. Conclusion: Somatostatin analogues can be used as a primary treatment for thyrotropin secreting pituitary adenomas when the patient is unable or unwilling to undergo surgery. It is use is associated with normalization of thyroid function and in some cases with a reduction in the adenoma size.
28
Cortes, Jorge E., Meir Wetzler, Jeffrey H. Lipton, H. Jean Khoury, Patricia Kropf, Mauricette Michallet, Michele Baccarani, et al. "Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)." Blood 122, no. 21 (November 15, 2013): 2743. http://dx.doi.org/10.1182/blood.v122.21.2743.2743.
Full textAbstract:
Abstract Introduction Subcutaneous (SC) omacetaxine mepesuccinate (OMA) is indicated for the treatment of CP and AP CML in adults with resistance/intolerance (R/I) to ≥2 tyrosine kinase inhibitors (TKIs). Unlike TKIs, OMA inhibits protein synthesis and is not a direct inhibitor of Bcr-Abl kinase activity. The clinical activity of OMA was demonstrated in a combined cohort of patients from 2 single-arm trials. The cohort consisted of patients who had received ≥2 approved TKIs and, at a minimum, documented evidence of R/I to dasatinib and/or nilotinib. This is the final ≥24-month follow-up analysis in a cohort subset from the 2 studies as originally approved by the FDA. Methods Patients received OMA 1.25 mg/m2 bid SC in 28-day cycles: 14 days for induction and 7 days as maintenance, adjusted for tolerability. Primary endpoints were major cytogenetic response (MCyR) for CP and major hematologic response (MaHR) for AP. Secondary objectives included time to onset and duration of response, progression-free survival (PFS), overall survival (OS), and adverse events (AEs). Survival data were collected after study discontinuation. Efficacy was analyzed by a data monitoring committee (DMC) on-study and investigators during follow-up for the cohort used for approval of OMA, which excluded patients with a best response at baseline or from a site without verified protocol compliance. Safety was analyzed for all CP and AP patients receiving SC OMA. Results As of October 12, 2012, the efficacy analysis cohort included 76 CP and 35 AP patients. The safety group included 163 patients (108 CP and 51 AP, plus 4 AP patients from a prior study). The majority of the 76 CP (median age, 59 y; range, 26-83 y) and 35 AP patients (median age, 64 y; range, 23-83 y) had received hydroxyurea (CP 41/76, AP 22/35) and 3 prior TKIs (CP 36/76, AP 22/35). At data cutoff, 5 CP patients and 1 AP patient continued OMA treatment (CP: 57, 43, 57, 52, and 48 months; AP: 52 months). Median treatment duration was 7.5 (range, 0-55.6) months for CP and 1.6 (0-49.7) months for AP patients. Median total months of follow-up for survival was 29.5 (95% CI, 17.6-36.4) for CP and 14.3 (95% CI, 4.7-18.7) for AP patients. Of patients receiving ≥2 cycles, 53/60 CP and 16/26 AP patients had a cycle delay; median number of cycles requiring delay per patient were 4 (CP) and 1 (AP). DMC-assessed responses were unchanged at 24 months; only investigator assessments were performed during follow-up. The MCyR rate for CP was 18% (14/76) with a mean time to onset of 3.5 months and median duration of 12.5 months. For AP, the MaHR rate was 14% (5/35) with a mean time to onset of 2.3 months and median duration of 4.7 months. No AP patients achieved MCyR. For ongoing patients, responses at data cutoff were complete cytogenetic response for all CP patients and hematologic improvement for the AP patient. Median PFS was 9.6 months for CP and 3.6 months for AP patients. At data cutoff, 16 CP and 1 AP patients had not progressed. Survival data were collected after therapy discontinuation; however, of the 6 patients in the efficacy cohort who remained on treatment at data cutoff, 2 (both CP) lost response as assessed by investigators. Based on the 24-month update, median OS was extended from 33.9 to 40.3 (95% CI, 23.8 to not reached) months for CP patients and was unchanged for AP patients at 14.3 (95% CI, 6.7-18.7) months (Figure). Safety and tolerability across the 24-month analysis were unchanged from the original analysis. The most common AEs (≥20%) were thrombocytopenia, anemia, neutropenia, diarrhea, nausea, fatigue, asthenia, and pyrexia for CP and AP patients; leukopenia and headache were ≥20% for CP only; febrile neutropenia was ≥20% for AP only. Patients with severe myelosuppression were at risk for infections and hemorrhage. Grade 3/4 hematologic laboratory toxicities for CP and AP patients were thrombocytopenia (CP 92/108, AP 44/50), neutropenia (CP 88/108, AP 35/50), leukopenia (CP 82/108, AP 30/50), and anemia (CP 65/108, AP 39/50). There were 53 deaths in the CP and 38 in the AP groups in the ≥24-month period; the most common causes were disease progression (25, 15), unknown (13, 17), sepsis (5, 0), and hemorrhage (cerebral [2, 3], pulmonary [1, 1]). Conclusions This 24-month update demonstrates that OMA induces clinically meaningful and durable responses in a subset of heavily pretreated patients with CP or AP CML who failed prior TKI therapies. Most grade 3/4 AEs were related to myelosuppression. Support: Teva BPP R&D, Inc. Disclosures: Cortes: BMS : Research Funding; Novartis: Research Funding; Pfizer: Consultancy, Research Funding; Teva: Consultancy, Research Funding; Ariad: Consultancy, Research Funding. Wetzler:Teva: Honoraria, Membership on an entity’s Board of Directors or advisory committees. Lipton:Ariad: Consultancy, Equity Ownership, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Teva: Consultancy, Honoraria, Research Funding. Khoury:Teva: Honoraria. Michallet:Astellas: Honoraria; Merck: Honoraria; Genzyme: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen-Cilag: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Research Funding; Teva: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria; BMS: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding. Baccarani:BMS: Consultancy, Honoraria; Ariad: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Teva: Consultancy; Novartis: Consultancy, Honoraria. Rea:BMS: Honoraria; Teva: Honoraria; Novartis: Honoraria. Chuah:BMS: Honoraria; Novartis: Honoraria. Parikh:Roche: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Dr Reddys: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Boehringer Ingelheim: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Glenmark: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Eisai: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Spectrum Pharmaceuticals: Equity Ownership; OncoRx: Equity Ownership; Biocon: Research Funding; GSK: Research Funding; Intas: Research Funding; Alkem: Research Funding. Li:PharmaStat, LLC: Consultancy. Munteanu:Teva: Employment, Equity Ownership. Brown:Teva: Employment, Equity Ownership. Nicolini:Novartis: Consultancy, Honoraria, Research Funding; BMS: Honoraria; Teva: Honoraria; Ariad Pharmaceuticals: Honoraria; Pfizer: Honoraria.
29
Shimada, Masumi, Hideyoshi Yokosawa, and Hiroyuki Kawahara. "OMA-1 is a P granules-associated protein that is required for germline specification in Caenorhabditis elegans embryos." Genes to Cells 11, no. 4 (April 2006): 383–96. http://dx.doi.org/10.1111/j.1365-2443.2006.00945.x.
Full text
30
Sánchez-Borges, Mario, Enrique Fernández-Caldas, Arnaldo Capriles-Hulett, and Fernan Caballero-Fonseca. "Mite-induced Inflammation: More than Allergy." Allergy & Rhinology 3, no. 1 (January 2012): ar.2012.3.0025. http://dx.doi.org/10.2500/ar.2012.3.0025.
Full textAbstract:
Clinical observations have suggested that there is an association of atopic conditions with hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs). This relationship has been especially present in patients allergic to mites. This study was designed to review clinical and experimental evidence linking atopy, mite allergy, and hypersensitivity to aspirin and NSAIDs and discuss the possible mechanisms explaining this association. A review of the medical literature concerning the association of atopic diseases, mite hypersensitivity, and intolerance to NSAIDs using PubMed and other relevant articles is presented. NSAID-sensitive patients are frequently atopic and allergic to mites, and patients who develop oral mite anaphylaxis (OMA) show an increased prevalence of NSAID hypersensitivity. The study of atopic, mite-sensitive patients, who experience urticaria and angioedema when exposed to NSAIDs and patients with OMA suggests an interesting interaction between atopic allergy and disorders of leukotriene synthesis or metabolism. Various mechanisms that could be involved in this interaction are presented, including genetic factors, inhibition of cyclooxygenase-1, and other effects (not related to IgE sensitization) of mite constituents on the immune system. The association of mite hypersensitivity with aspirin/NSAIDs intolerance has been confirmed and provides additional clues to various nonallergic pathways that may contribute to the acute and chronic inflammatory process observed in atopic, mite-allergic, individuals. The clinical relevance of these observations is presently under investigation.
31
Kitsing, Maie, Karin Täht, and Hasso Kukemelk. "Kooli mikrokliima: õpetajate toetav käitumine ja õpilaste tulemuslikkus." Eesti Haridusteaduste Ajakiri. Estonian Journal of Education 3, no. 1 (April 30, 2015): 127–47. http://dx.doi.org/10.12697/eha.2015.3.1.06.
Full textAbstract:
Uuringu eesmärk oli selgitada õpetaja toetava käitumise ja õpilase õppetööd takistava käitumise seoseid õpilaste õpitulemustega, arvestades õpilaste otsiaalmajanduslikku tausta. Valimi moodustasid PISA 2012. aasta uuringus osalenud eesti õppekeelega koolide 3570 õpilast ja nende koolide juhid. Töös kasutati nelja PISA 2012. aasta andmebaasi muutujat: 1) õpilaste keskmist tulemust kolmes hindamisvaldkonnas (matemaatika, loodusteadused, kirjutamine); 2) õpilaste sotsiaalmajanduslikku tausta; 3) õpilaste käitumise indeksit, mis koondas õpilastega seotud õppetööd häirivad tunnused; 4) õpetajate käitumist iseloomustavaid tunnuseid, mis takistavad õppetööd. Uurimistulemustest ilmnes statistiliselt oluline, kuid väga nõrk seos õpilaste keskmise soorituse ja õpetajatepoolse õppetööd takistava käitumise vahel. Õpilasteja õpetajatepoolse õppetööd takistava käitumise seos oli mõõdukas. Sotsiaalmajandusliku tausta põhjal prognoositust madalama ja kõrgema tulemuse saanud õpilaste gruppide puhul avaldus mõõdukas seos õpilaste- ja õpetajatepoolse õppetööd takistava käitumise järgmiste tunnuste vahel: õpilaste ja õpetajate halvad suhted (alasooritajate grupis r = 0,54; ülesooritajate grupis r = 0,51) ja õpetajad ei arvesta iga üksiku õpilase vajadustega (alasooritajate grupis r = 0,40; ülesooritajate grupis r = 0,43). Alasooritajate grupi puhul osutus mõõdukaks seoseks veel tunnus õpilasi ei julgustata saavutama kogu oma potentsiaali (r = 0,41), seevastu ülesooritajate grupis ilmnes mõõdukas seos õpilase käitumise ja õpetaja käitumist iseloomustava tunnuse õpetajad peavad õpetama ühes ja samas klassis erineva etnilise taustaga (st keel, kultuur) õpilasi puhul (r = 0,40). Kahe grupi seoste võrdlemisel osutus statistiliselt oluliselt erinevaks kaks tunnust: õpilasi ei julgustata saavutama kogu oma potentsiaali ja õpetajad peavad õpetama ühes ja samas klassis erinevate võimetega õpilasi. Summary
32
RAO, SAJID EJAZ, SOHAIL MUZAMMIL, and ABDUL HAFEEZ KHAN. "SYNDESMOSIS FIXATION IN BIMALLEOLAR WEBER C ANKLE FRACTURES;." Professional Medical Journal 15, no. 01 (March 10, 2008): 49–53. http://dx.doi.org/10.29309/tpmj/2008.15.01.2696.
Full textAbstract:
Objective: To study the influence of size of screws for syndesmosis fixationin bimalleolar Weber C ankle fracture. Design: A prospective randomised controlled clinical trial. Place and Durationof Study: Orthopaedic Department at Combined Military Hospital Malir. Period: From October 2002 to September2005. Patients and Methods: 17 consecutive young active patients with Weber type C bimalleolar ankle fractureshaving syndesmotic injuries treated with open reduction and internal fixation were randomly allocated to two groups.1 2 In group I (n = 9) 3.5mm small fragment and in group II (n =8) 4.5mm large fragment AO cortical screws were usedfor syndesmotic fixation. All patients were followed up for 12 months. Fracture healing or loss of reduction ofsyndesmosis was taken as the study end point. Hardware loosening or breakage and need for hardware removal werethe outcome measures. Subjective and objective assessment with Olerud-Molander Ankle (OMA) scores , range of 1motion and radiographic criteria was done. Results: Loss of reduction was not seen in any patient in both groups.Comparing two groups using paired sample t-test, there was no difference in screw loosening and breakage (p values> 0.05). We did not find a statistically significant difference between range of motion (p = 1.08) and OMA score (p-value= 0.805). Conclusion: Size of the syndesmotic screw does not appear to influence healing of syndesmotic injury.Screw loosening, which can result in reduced range of ankle motion postoperatively was more common in smallerscrew group though the difference was not significant.
33
Butragueño Díaz-Guerra, Belén, Javier Fco Raposo Grau, and María Asunción Salgado de la Rosa. "Polyhedral communication in architecture." Advances in Building Education 5, no. 1 (April 16, 2021): 9. http://dx.doi.org/10.20868/abe.2021.1.4566.
Full textAbstract:
There are multiple communicative strategies in architecture depending on the target audience. The mechanisms of representation may radically vary when the recipient is the client, the constructor, the curator, a colleague or even an instructor (1). As an example, the approach may be mainly visual when the target is the client. However, it may be strictly structural to start a conversation with a peer ad mostly conceptual when pointing to the jury members in a competition. In certain cases, the adaptation of the graphic language to the different scenarios leads to such a distortion on the message that the original project is hardly recognizable. To illustrate this point, the article will focus on the project of the Public Seattle Library, designed by the architect Rem Koolhaas. The analysis of five different communicative strategies of the project show peculiar and unequal graphic narrations: from the concept book of the competition, the website of LMN (the American partners of Rem Koolhaas- OMA in this particular project), the website of OMA, the coverage on the Seattle press, the Library Brochure for teenagers and the approach developed on the "Content" book. Rem Koolhaas coined the concept of "design of information" to express the fundamental relationship between the message and media in architecture. In his practice, the communicative strategy is present from the beginning of the design process till the final stages. In this article, the thoughtful comparison of these examples will enable to extract conclusions on the use of communication in architectural design and reflect on the iconic and communicative dimension of architecture in general.
34
Li, Wei, Leah R. DeBella, Tugba Guven-Ozkan, Rueyling Lin, and Lesilee S. Rose. "An eIF4E-binding protein regulates katanin protein levels in C. elegans embryos." Journal of Cell Biology 187, no. 1 (September 28, 2009): 33–42. http://dx.doi.org/10.1083/jcb.200903003.
Full textAbstract:
In Caenorhabditis elegans, the MEI-1–katanin microtubule-severing complex is required for meiosis, but must be down-regulated during the transition to embryogenesis to prevent defects in mitosis. A cullin-dependent degradation pathway for MEI-1 protein has been well documented. In this paper, we report that translational repression may also play a role in MEI-1 down-regulation. Reduction of spn-2 function results in spindle orientation defects due to ectopic MEI-1 expression during embryonic mitosis. MEL-26, which is both required for MEI-1 degradation and is itself a target of the cullin degradation pathway, is present at normal levels in spn-2 mutant embryos, suggesting that the degradation pathway is functional. Cloning of spn-2 reveals that it encodes an eIF4E-binding protein that localizes to the cytoplasm and to ribonucleoprotein particles called P granules. SPN-2 binds to the RNA-binding protein OMA-1, which in turn binds to the mei-1 3′ untranslated region. Thus, our results suggest that SPN-2 functions as an eIF4E-binding protein to negatively regulate translation of mei-1.
35
Anuar, M. Azhan, A. A. Mat Isa, A. R. Zamri, and M. F. M. Said. "Ambient Response Modal Analysis on a CEM-1 Single-Layer Printed Circuit Board." Applied Mechanics and Materials 393 (September 2013): 683–87. http://dx.doi.org/10.4028/www.scientific.net/amm.393.683.
Full textAbstract:
Since the level of vibration always depends on the natural frequencies of the system, it is important to know the modal parameters of such system to control failure and provide prevention actions. The demand for structurally reliable Printed Circuit Boards (PCB) has increased as more functions are required from electronic products along with less weight and smaller size. This imposes certain limitations and critical requirements. In this paper, investigation on the dynamic characteristics of CEM-1 Single-layer PCB using Operational Modal Analysis (OMA, or often called Output-Only or Ambient Modal analysis), is presented. The Frequency Domain Decomposition (FDD) and Enhanced Frequency Domain Decomposition (EFDD) techniques are applied on the PCB with free-free end condition. Comparison of results between both techniques and also with the result from Experimental Modal Analysis (EMA), will be shown. The understanding on dynamic behaviour of this structure provides valuable insight into the nature of the response and remarkable enhancement of its model, strength and vibration.
36
van der A, R. J., M. A. F. Allaart, and H. J. Eskes. "Multi sensor reanalysis of total ozone." Atmospheric Chemistry and Physics 10, no. 22 (November 30, 2010): 11277–94. http://dx.doi.org/10.5194/acp-10-11277-2010.
Full textAbstract:
Abstract. A single coherent total ozone dataset, called the Multi Sensor Reanalysis (MSR), has been created from all available ozone column data measured by polar orbiting satellites in the near-ultraviolet Huggins band in the last thirty years. Fourteen total ozone satellite retrieval datasets from the instruments TOMS (on the satellites Nimbus-7 and Earth Probe), SBUV (Nimbus-7, NOAA-9, NOAA-11 and NOAA-16), GOME (ERS-2), SCIAMACHY (Envisat), OMI (EOS-Aura), and GOME-2 (Metop-A) have been used in the MSR. As first step a bias correction scheme is applied to all satellite observations, based on independent ground-based total ozone data from the World Ozone and Ultraviolet Data Center. The correction is a function of solar zenith angle, viewing angle, time (trend), and effective ozone temperature. As second step data assimilation was applied to create a global dataset of total ozone analyses. The data assimilation method is a sub-optimal implementation of the Kalman filter technique, and is based on a chemical transport model driven by ECMWF meteorological fields. The chemical transport model provides a detailed description of (stratospheric) transport and uses parameterisations for gas-phase and ozone hole chemistry. The MSR dataset results from a 30-year data assimilation run with the 14 corrected satellite datasets as input, and is available on a grid of 1× 1 1/2° with a sample frequency of 6 h for the complete time period (1978–2008). The Observation-minus-Analysis (OmA) statistics show that the bias of the MSR analyses is less than 1% with an RMS standard deviation of about 2% as compared to the corrected satellite observations used.
37
Shirayama, Masaki, Martha C. Soto, Takao Ishidate, Soyoung Kim, Kuniaki Nakamura, Yanxia Bei, Sander van den Heuvel, and Craig C. Mello. "The Conserved Kinases CDK-1, GSK-3, KIN-19, and MBK-2 Promote OMA-1 Destruction to Regulate the Oocyte-to-Embryo Transition in C. elegans." Current Biology 16, no. 1 (January 2006): 47–55. http://dx.doi.org/10.1016/j.cub.2005.11.070.
Full text
38
Shirayama, Masaki, Martha C. Soto, Takao Ishidate, Soyoung Kim, Kuniaki Nakamura, Yanxia Bei, Sander van den Heuvel, and Craig C. Mello. "The Conserved Kinases CDK-1, GSK-3, KIN-19, and MBK-2 Promote OMA-1 Destruction to Regulate the Oocyte-to-Embryo Transition in C. elegans." Current Biology 16, no. 1 (January 2006): 118. http://dx.doi.org/10.1016/j.cub.2005.12.029.
Full text
39
Juck, Gregory, Verapaz Gonzalez, Ann-Christine Olsson Allen, Meredith Sutzko, Kody Seward, and Mark T. Muldoon. "Romer Labs RapidChek®Listeria monocytogenes Test System for the Detection of L. monocytogenes on Selected Foods and Environmental Surfaces." Journal of AOAC INTERNATIONAL 101, no. 5 (September 1, 2018): 1490–507. http://dx.doi.org/10.5740/jaoacint.18-0035.
Full textAbstract:
Abstract The Romer Labs RapidChek®Listeria monocytogenes test system (Performance Tested Method 011805) was validated against the U.S. Department of Agriculture-Food Safety and Inspection Service Microbiology Laboratory Guidebook (USDA-FSIS/MLG), U.S. Food and Drug Association Bacteriological Analytical Manual (FDA/BAM), and AOAC Official Methods of Analysis (AOAC/OMA) cultural reference methods for the detection of L. monocytogenes on selected foods including hot dogs, frozen cooked breaded chicken, frozen cooked shrimp, cured ham, and ice cream, and environmental surfaces including stainless steel and plastic in an unpaired study design. The RapidChek method uses a proprietary enrichment media system, a 44–48 h enrichment at 30 ± 1°C, and detects L. monocytogenes on an immunochromatographic lateral flow device within 10 min. Different L. monocytogenes strains were used to spike each of the matrixes. Samples were confirmed based on the reference method confirmations and an alternate confirmation method. A total of 140 low-level spiked samples were tested by the RapidChek method after enrichment for 44–48 h in parallel with the cultural reference method. There were 88 RapidChek presumptive positives. One of the presumptive positives was not confirmed culturally. Additionally, one of the culturally confirmed samples did not exhibit a presumptive positive. No difference between the alternate confirmation method and reference confirmation method was observed. The respective cultural reference methods (USDA-FSIS/MLG, FDA/BAM, and AOAC/OMA) produced a total of 63 confirmed positive results. Nonspiked samples from all foods were reported as negative for L. monocytogenes by all methods. Probability of detection analysis demonstrated no significant differences in the number of positive samples detected by the RapidChek method and the respective cultural reference method.
40
Arco, Yolanda, Inmaculada Llamas, Fernando Martínez-Checa, Montserrat Argandoña, Emilia Quesada, and Ana del Moral. "epsABCJ genes are involved in the biosynthesis of the exopolysaccharide mauran produced by Halomonas maura." Microbiology 151, no. 9 (September 1, 2005): 2841–51. http://dx.doi.org/10.1099/mic.0.27981-0.
Full textAbstract:
The moderately halophilic strain Halomonas maura S-30 produces a high-molecular-mass acidic polymer (4·7×106 Da) composed of repeating units of mannose, galactose, glucose and glucuronic acid. This exopolysaccharide (EPS), known as mauran, has interesting functional properties that make it suitable for use in many industrial fields. Analysis of the flanking regions of a mini-Tn5 insertion site in an EPS-deficient mutant of H. maura, strain TK71, led to the identification of five ORFs (epsABCDJ), which form part of a gene cluster (eps) with the same structural organization as others involved in the biosynthesis of group 1 capsules and some EPSs. Conserved genetic features were found such as JUMPstart and ops elements, which are characteristically located preceding the gene clusters for bacterial polysaccharides. On the basis of their amino-acid-sequence homologies, their putative hydropathy profiles and the effect of their mutations, it is predicted that EpsA (an exporter-protein homologue belonging to the OMA family) and EpsC (a chain-length-regulator homologue belonging to the PCP family) play a role in the assembly, polymerization and translocation of mauran. The possibility that mauran might be synthesized via a Wzy-like biosynthesis system, just as it is for many other polysaccharides, is also discussed. This hypothesis is supported by the fact that EpsJ is homologous with some members of the PST-exporter-protein family, which seems to function together with each OMA–PCP pair in polysaccharide transport in Gram-negative bacteria, transferring the assembled lipid-linked repeating units from the cytoplasmic membrane to the periplasmic space. Maximum induction of the eps genes is reached during stationary phase in the presence of 5 % (w/v) marine salts.
41
Oliveira, Joana Correia, Filipa Costa Sousa, Inês Gante, and Margarida Figueiredo Dias. "Awareness of the Causes Leading to Surgical Ablation of Ovarian Function in Premenopausal Breast Cancer—A Single-Center Analysis." Medicina 57, no. 4 (April 16, 2021): 385. http://dx.doi.org/10.3390/medicina57040385.
Full textAbstract:
Background and Objectives: Ovarian surgical ablation (OSA) in estrogen receptor-positive (ER+) breast cancer is usually performed to halt ovarian function in premenopausal patients. Since alternative pharmacological therapy exists and few studies have investigated why surgery is still performed, we aimed to analyze the reasons for the use of OSA despite the remaining controversy. Materials and Methods: Premenopausal ER+ breast cancer patients treated at a tertiary center (2005–2011) were selected, and patients with germline mutations were excluded. Results: Seventy-nine patients met the inclusion criteria. Globally, the main reasons for OSA included: continued menstruation despite hormone therapy with or without ovarian medical ablation (OMA) (34.2%), patient informed choice (31.6%), disease progression (16.5%), gynecological disease requiring surgery (13.9%), and tamoxifen intolerance/contraindication (3.8%). In women aged ≥45 years, patient choice was significantly more frequently the reason for OSA (47.4% versus 17.1% (p = 0.004)). For those aged <45 years, salvation attempts were significantly more frequent as compared to older women (26.8% versus 5.3% (p = 0.01)). In 77.8% of women undergoing OSA with menstrual cycle maintenance, surgery was performed 1–5 years after diagnosis, while surgery was performed earlier (0–3 months after diagnosis) in patients undergoing OSA as an informed choice (56.0%), as a salvation attempt (53.8%), or due to gynecological disease (63.6%). The leading reason for OSA in women previously undergoing OMA was continued menstruation (60.0%). Conclusions: This study suggests a possible failure of pharmacological ovarian suppression and reinforces the need for shared decision-making with patients when discussing treatment strategies, although validation by further studies is warranted due to our limited sample size.
42
van der A, R. J., M. A. F. Allaart, and H. J. Eskes. "Multi sensor reanalysis of total ozone." Atmospheric Chemistry and Physics Discussions 10, no. 4 (April 28, 2010): 11401–48. http://dx.doi.org/10.5194/acpd-10-11401-2010.
Full textAbstract:
Abstract. A single coherent total ozone dataset, called the Multi Sensor Reanalysis (MSR), has been created from all available ozone column data measured by polar orbiting satellites in the near-ultraviolet Huggins band in the last thirty years. Fourteen total ozone satellite retrieval datasets from the instruments TOMS (on the satellites Nimbus-7 and Earth Probe), SBUV (Nimbus-7, NOAA-9, NOAA-11 and NOAA-16), GOME (ERS-2), SCIAMACHY (Envisat), OMI (EOS-Aura), and GOME-2 (Metop-A) have been used in the MSR. As first step a bias correction scheme is applied to all satellite observations, based on independent ground-based total ozone data from the World Ozone and Ultraviolet Data Center. The correction is a function of solar zenith angle, viewing angle, time (trend), and stratospheric temperature. As second step data assimilation was applied to create a global dataset of total ozone analyses. The data assimilation method is a sub-optimal implementation of the Kalman filter technique, and is based on a chemical transport model driven by ECMWF meteorological fields. The chemical transport model provides a detailed description of (stratospheric) transport and uses parameterisations for gas-phase and ozone hole chemistry. The MSR dataset results from a 30-year data assimilation run with the 14 corrected satellite datasets as input, and is available on a grid of 1×1½ degrees with a sample frequency of 6 h for the complete time period (1978–2008). The Observation-minus-Analysis (OmA) statistics show that the bias of the MSR analyses is less than 1 percent with an RMS standard deviation of about 2 percent as compared to the corrected satellite observations used.
43
Colovic, Radoje, Nikica Grubor, Marjan Micev, Natasa Colovic, Vera Todorovic, and Milena Cosic-Micev. "Two pp-omas of the head of the pancreas one of which with central necrosis fistulated into the duodenum." Srpski arhiv za celokupno lekarstvo 131, no. 5-6 (2003): 259–65. http://dx.doi.org/10.2298/sarh0306259c.
Full textAbstract:
PP omas are rare, usually malignant tumors of the PP cells of the Langerhan?s islets which secrete pancreatic polipeptide. The authors present two women operated for PP-omas of the pancreas. The first was 55 year-old woman in whom we did a cephalic duodenopan-createctomy (Whipple's procedure) for the tumor of the head of the pancreas with central cavity containing gas due to comunication with the duodenum. Imunohistochemistry showed a PP oma with strong generalised immunoreactivity with antibodies against Chromogra-min A, neuron specific enolasa and PP with more the 95% of tumor cells and coexpression of somatostatine in 35% and VIP in less then 5% of tumor cells. Following uneventful recovery the patient stayed symptom free so far and put 20 kilograms in weight. The second patient was 19 year-old girl with a multinodal tumor of almost the entire pancreas in whom a local excision of the nodal mass of the head of the pancreas had been carried out in the other hospital, three years ago and relaparotomy and tumor biopsy a month before admission to our institution. In her we did a total duodenopancreatectomy and standard limphadenectomy for a multinodal mass ocupying almost the entire pancreas. Immunohistochemistry showed a strong generalised immunoreactivity with antibodies agains Chromographin A, Neuron speciphic enolasa and PP for more then 95% of tumor's cells. Glucagon was expressed in few focuses (in less then 1% of cells), somatostatin was expressed very rarely in single cells while the rest of tumor markers did not show a visible immunologic reactions in the majority of tumor's cells. Three years after surgery she died due to multiple liver secondaries.
44
Khadka, Ram B., Sundar M. Shrestha, Hira K. Manandhar, and Gopal BKC. "Study on Differential Response of Pyricularia grisea Isolates from Rice, Finger Millet and Panicum sp. with Local and Alien Media, and Their Host Range." Nepal Journal of Science and Technology 13, no. 2 (March 8, 2013): 7–14. http://dx.doi.org/10.3126/njst.v13i2.7707.
Full textAbstract:
Blast (Pyricularia grisea) is an economically important disease of rice and finger millet in Nepal. Isolates of the fungus from different hosts differed in their response in media for mycelial growth and sporulation. Radial mycelial growth (RMG) and days of sporulation (DOS) of P. grisea were studied by culturing three fungal isolates from rice, finger millet and Panicum sp. on six different media: prune agar (PA), oat meal agar (OMA), potato dextrose agar (PDA), finger millet leaf decoction agar (FLDA), finger millet polish agar (FPA) and finger millet meal agar (FMA). The highest RMG was found in the isolates from finger millet and the lowest in the isolates from rice. The shortest DOS (1 week) was found in the isolate from rice and the longest (>2 weeks) in the isolate from finger millet. Among the different media used, PA and OMA were found to be the best for mycelial growth and sporulation of the isolates both from rice and finger millet. The shape, color and compactness of the fungal colonies varied with the media and isolates used. Cross inoculation studies showed that the fungus isolates from rice were able to infect all the plant species (rice, finger millet, Panicum sp., Eleusine indica and Setaria sp.) while isolates from finger millet were only able to infect three plant species (E. coracana, Setaria sp. and E. indica). This shows that the weed management is more important in finger millet fields than in rice field to manage the blast disease; and growing of rice adjacent to finger millet field is dangerous for blast epidemics in finger millet since rice serves as the source of inoculums. Nepal Journal of Science and Technology Vol. 13, No. 2 (2012) 7-14 DOI: http://dx.doi.org/10.3126/njst.v13i2.7707
45
Chen, Gongfa, Zhihua Wu, Chunjian Gong, Jiqiao Zhang, and Xiaoli Sun. "DIC-Based Operational Modal Analysis of Bridges." Advances in Civil Engineering 2021 (February 4, 2021): 1–13. http://dx.doi.org/10.1155/2021/6694790.
Full textAbstract:
A new method has been proposed to identify the natural frequencies and mode shapes of a bridge model, in which the digital image correlation (DIC) technique is used to track the dynamic displacement. A key issue in vibration-based damage detection for a bridge is to determine its modal parameters. It is difficult to use traditional acceleration sensors to obtain the accurate mode shapes of bridges as the sensors are only deployed on a few measurement points of the bridges. In this article, the DIC technique is used to capture the movement of the entire experimental bridge model. A steel truss is used as a bridge model and stimulated by a hammer; its dynamic displacement is recorded by using a digital video camera. The correlation analysis is used to track the displacement of the points of interest, and their displacement time histories are inputted into a modal analysis system; the natural frequencies and mode shapes of the bridge model were obtained by both operational modal analysis (OMA) and traditional experimental modal analysis (EMA) methods. (1) The DIC results are compared with those obtained by a traditional acceleration sensor-based method; the natural frequencies obtained by the two measurement methods are very close. (2) The DIC results are sensitive to the amplitude of the measured displacement and the shooting distance; small displacement amplitudes and long shooting distance may result in the low quality of the measured time-history curves, and low-frequency noise signals might be observed in their power spectral density (PSD) curves, while they can be easily solved by the filtering method in this article. (3) In addition, the first frequencies obtained by EMA and OMA are very close, which validates the applicability of the DIC measurement under ambient excitation. The research has illustrated the feasibility of the DIC method for obtaining the modal parameters of the bridges.
46
Luhtinen, Vilma, Anu Immonen, Anne Mäkikangas, Mari Huhtala, and Taru Feldt. "Työn tuunaamisen profiilit sosiaali- ja terveysalan organisaatiossa: yhteydet työhyvinvointiin." Työelämän tutkimus 19, no. 2 (June 15, 2021): 197–221. http://dx.doi.org/10.37455/tt.99646.
Full textAbstract:
Työn tuunaaminen on oma-aloitteista työn kehittämistä työn voimavaroja ja vaatimuksia muokkaamalla. Tutkimme, millaisia tuunausprofiileja voidaan löytää kolmesta erilaisesta tuunaustavasta, jotka olivat työn voimavarojen lisääminen, työn vaatimusten lisääminen ja työn vaatimusten optimoiminen. Selvitimme myös, miten työhyvinvointi vaihtelee profiileissa. Sähköiseen kyselyyn osallistui 1 024 sosiaali- ja terveysalan organisaation työntekijää. K-keskiarvojen klusterianalyysin avulla tunnistimme neljä työn tuunaamisen profiilia: aktiiviset tuunaajat (19 %, monipuolinen tuunaaminen), optimoivat tuunaajat (21 %, työn vaatimusten optimointi), passiiviset tuunaajat (27 %, keskimääräistä vähemmän tuunausta) ja keskiverrot tuunaajat (34 %, keskimääräisesti tuunauksen eri tapoja). Moniulotteinen kovarianssianalyysi osoitti, että aktiiviset tuunaajat kokivat eniten työn imua ja työn merkityksellisyyttä. Passiiviset tuunaajat kokivat niitä vähiten. Aktiivisilla tuunaajilla ja optimoivilla tuunaajilla oli hieman muita profiileja enemmän emotionaalista uupumusta. Nuoremmat työntekijät olivat vanhempia työntekijöitä aktiivisempia työn tuunaajia. Johtopäätöksenä voidaan todeta, että sote-alalla kannattaa edistää työn tuunaamisen tapoja, sillä monipuolinen työn tuunaaminen oli yhteydessä erityisesti työn imuun ja työn merkityksellisyyteen.
47
Saand, Aisha R., Monica Flores, Sura Alqaisi, and Ossama Lashin. "Thyrotropin-Secreting Pituitary Adenoma Successfully Treated With Cabergoline." Journal of the Endocrine Society 5, Supplement_1 (May 1, 2021): A967—A968. http://dx.doi.org/10.1210/jendso/bvab048.1977.
Full textAbstract:
Abstract Background: Thyrotropin secreting pituitary adenomas (TSH-oma) account for less than 1% of pituitary adenomas and are a rare cause of hyperthyroidism. In this case, we describe the safe use of cabergoline with the subsequent achievement of euthyroid levels and the resolution of symptoms. Clinical Case: A 67-year-old female with a presumed history of hypothyroidism for the last 3 years managed with Armour thyroid was referred for fatigue associated with palpitations, intermittent diarrhea, insomnia, and anxiety. Her TSH was noted to be suppressed at that time, and her Amour thyroid was changed to Levothyroxine 25 mcg daily, which was eventually stopped as her symptoms persisted. Follow-up thyroid function tests (TFTs) showed elevated TSH (8.60 µU/mL, reference range 0.340 - 5.600 µU/mL), and elevated free T3 (10.8 pg/mL, reference range 2.7-4.7 pg/mL) and free T4 (2.0 ng/dL, reference range 0.8-1.5 ng/dL) levels. Further laboratory workup including basal prolactin, LH, FSH, hCG α-subunit, IGF-1, and ACTH levels were within the normal range. Physical examination showed diffuse thyroid enlargement. An I-123 thyroid uptake and scan showed uniform uptake throughout the gland with no focal hyperintense areas. A dedicated pituitary MRI was performed and revealed an 8 mm microadenoma in the posterior left adenohypophysis. The patient wanted to avoid any invasive treatment and refused trans-sphenoidal surgery and medical therapy was chosen. Unfortunately, using a somatostatin analog as part of the standard medical treatment was not an option due to the high cost and lack of insurance coverage. For these reasons, a trial of cabergoline was started to suppress TSH secretion. Atenolol 25 mg daily was added temporarily for the management of her sympathetic symptoms. On periodic follow-up, her symptoms gradually subsided, and TFTs remained within normal limits. Treatment was continued for one year. Conclusion: Clinical manifestations of hyperthyroidism with biochemical evidence of elevated thyroid hormone levels and TSH levels should raise a strong suspicion for central or secondary hyperthyroidism due to TSH secreting pituitary adenoma. Cabergoline might represent an effective alternative form of medical treatment for TSH-oma in certain situations where the first line therapeutic options are refractory, contraindicated, or declined.
48
Ben Labidi, Mouna, Marwa Mejri, Adel A. A. B. Shahin, Jean-Pierre Quignard, Monia Trabelsi, and Abderraouf Ben Faleh. "Otolith fluctuating asymmetry in Boops boops (Actinopterygii, Sparidae) from two marine stations (Bizerte and Kelibia) in Tunisian waters." Journal of the Marine Biological Association of the United Kingdom 100, no. 7 (November 2020): 1135–46. http://dx.doi.org/10.1017/s0025315420001022.
Full textAbstract:
AbstractFor the first time, saccular otolith shape and size were analysed in 254 samples of the bogue Boops boops collected from the marine stations of Bizerte and Kelibia situated in north-east Tunisia. The objectives were (1) to examine the inter- and intra-population variation in the otolith shape and size, including length (Lo), width (Wo) and area (Ao) measurements, and (2) to assess the relationship between otolith mass asymmetry (OMA) and total fish length (TL). In addition, the impact of pollution present in these two stations on the shape and size of the otolith in relation to the TL was discussed. Analyses of the otolith shape and biometric data showed a statistically significant asymmetry in the otolith shape (P < 0.0001) between the right and left sides within the population of Bizerte, as well as between the otoliths from the same right-right and left-left sides between the populations of Bizerte and Kelibia. Similarly, a significant Wo asymmetry (P < 0.05) was recorded within the population of Kelibia. Conversely, a significant symmetry was detected in Lo and Ao (P > 0.05) between the right and left sides within the populations of Bizerte and Kelibia. Moreover, the level of asymmetry of Ao was higher than that of Lo and Wo in both populations. Nevertheless, Student's t-test showed no statistically significant differences (P > 0.05) for Lo, Wo and Ao in relation to the means of TL between the three groups of the populations of Bizerte and Kelibia, although significant differences (P < 0.05) were found by using box plots. Furthermore, no statistically significant relationship (P > 0.05) was detected between OMA and TL within and between the populations of Bizerte and Kelibia. The possible cause of fluctuating asymmetry (FA) in the otolith shape and size both within and/or between populations of the two stations has been discussed in relation to the instability of development induced by environmental stress associated with the variation in water temperature, salinity, depth, feeding conditions and pollutants present in these stations.
49
Soós, Zsuzsanna, Anna Czégeni, Ferenc Salamon, Mónika Salamon, István Kenessey, András Folyovich, Tibor Tihanyi, and Gábor Winkler. "A case of glucose-sensitive insulinoma accompanied by slightly elevated serum insulin levels and persisting convulsions after the surgically removed neuroendocrine tumor." Orvosi Hetilap 154, no. 2 (January 2013): 69–73. http://dx.doi.org/10.1556/oh.2013.29522.
Full textAbstract:
Insul(in)oma is a usually solitary or, in some cases, multifocal tumor of pancreatic beta cells. It may be a component of multiple endocrine neoplasia type 1. or von Hippel-Lindau syndrome. In typical forms the diagnosis – based on the Whipple triad – is simple, however, it may be difficult to recognize in cases with near normal or only slightly elevated serum insulin levels, as well as in patients with known convulsive episodes. With the case presentation of an 81-year-old woman the authors draw attention to the pitfalls of the correct diagnosis. A special feature of the presented case is that convulsions persisted after surgical removal of the pancreatic neuroendocrine tumor verified with functional and imaging methods. Recurrant or residual tumor was not found, and morphological damage of the brain was absent. In the background of the continuing convulsions cerebrovascular alterations as well as the cytotoxic effect of the hypoglycemia-induced excessive glutamate production can be postulated. Orv. Hetil., 2013, 154, 69–73.
50
Pennartz, P. U., U. Löchner, H. Fuess, and T. Wroblewski. "Powder diffraction in the range of milliseconds." Journal of Applied Crystallography 25, no. 5 (October 1, 1992): 571–77. http://dx.doi.org/10.1107/s0021889892004102.
Full textAbstract:
Powder diffraction studies with synchrotron radiation were performed on a time scale down to 2.5 ms at the HASYLAB beamline B2 with a commercial 1024 pixel linear photodiode-array detector system (OMA III, EG&G–PARC). The flux rate of 2 x 108 photons s−1 at a wavelength of 1.26 Å achieved by using a toroidal mirror and a standard double-crystal Si(111) monochromator was measured with an ionization chamber at the focus. With a synthetic multilayer to select the desired wavelength instead of the standard monochromator, a flux rate of 1.5 x 1010 photons s−1 was measured at a wavelength of 1.31 Å. The shortest possible recording times for a complete powder pattern of calcium fluoride were 200 ms with the crystal monochromator and 2.5 ms with the multilayer. The angular resolution for both cases is discussed. The high-speed data collection was successfully applied with the double-crystal and multilayer monochromators to the recording of more-complex patterns and to monitor a phase transformation in order to demonstrate the feasibility of kinetic studies on the millisecond time scale.